Article
Opportunities and challenges following approval of resmetirom for MASH liver disease - Nature Medicine
Rating:
0.0
Views:
9
Likes:
1
Library:
1
The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value